On January 5, 2020, "China’s First Mechanical Circulatory Support Conference" and "The First Preparatory Meeting of Mechanical Circulatory Support (MCS) Branch of Chinese Society of Biomedical Engineering (CSBE) " sponsored by National Center for Cardiovascular Diseases (NCCD) and Fuwai Hospital were held in Beijing. The event invited experts from National Center for Medical Device Evaluation (NCMDE), National Medical Products Administration (NMPA) and National Institute for Food and Drug Control (NIFDC), universities, main enterprises, research institutions in the field of mechanical circulatory support, and more than 50 domestic surgical expert teams of large heart centers. Our CEO Dr. Chen was invited to participate in the meeting and give keynote speech as a representative of the research and development enterprises.
The meeting focused on the society preparation work, operation system and plan of the Mechanical Circulation Support Branch of CSBE. It also discussed on how to accelerate the clinical transformation of medical device research and development in this field and improve the clinical application effect of mechanical circulatory support devices. At the meeting, Dr. Chen delivered a keynote speech titled "Current Status and Future of Implantable Ventricle Assist Device". He introduced the market dynamics and technological evolution of VAD and analyzed the future development trend. At the same time, he shared the latest clinical application and test results of CH-VAD® of CH Biomedical, which gained high attention from the participants.
Dr. Chen is one of the founding members of the mechanical circulatory support branch of CSBE which consists of experts of regulation, industry, academy, and healthcare system in the field.
Through the establishment of an exchange platform in this field, experts in various fields of technology and clinical medicine will be gathered to strengthen interdisciplinary, multi-field, and cross-cutting innovative research to help our country's R&D and manufacturing capabilities of mechanical circulatory support.
On August 7, People’s Daily published an article titled Domestic Fully Magnetically Levitated VAD Serving Patients, commending CH Biomedical for breaking the international technological monopoly for developing a domestically produced, fully magnetically levitated VAD with independent intellectual property rights. The device is currently available in nearly 40 hospitals across China, enabling over 140 patients with advanced heart failure to embark on a “new life”.
Recently, at the 2022 China Medical Development Conference—widely regarded as the country’s premier medical forum—the Chinese Academy of Medical Sciences (CAMS) released two lists: China’s Major Medical Achievements of the 21st Century and China’s Important Medical Advancements in 2021. As a global innovator in the field of Ventricular Assist Devices (VADs), CH Biomedical’s independently developed CH-VAD (NMPA (A) 20213120987) was included in China’s Important Medical Advancements in 2021.
From 9th to 14th of June 2019, the Gordon Research Conference was held in Barcelona, Spain. The conference theme this year was on Mechanical Circulatory Support (MCS) and brought together world-renowned doctors, scholars, and researchers in MCS field. Dr. Chen, CEO of the company, and Dr. Lin, CTO were invited to attend the conference and delivered a plenary speech.
